Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
Miller, Vincent A, Prof, Hirsh, Vera, MD, Cadranel, Jacques, Prof, Chen, Yuh-Min, MD, Park, Keunchil, Prof, Kim, Sang-We, Prof, Zhou, Caicun, Prof, Su, Wu-Chou, Prof, Wang, Mengzhao, Prof, Sun, Yan, Prof, Heo, Dae Seog, Prof, Crino, Lucio, Prof, Tan, Eng-Huat, MD, Chao, Tsu-Yi, Prof, Shahidi, Mehdi, MD, Cong, Xiuyu Julie, PhD, Lorence, Robert M, MD, Yang, James Chih-Hsin, Prof
Published in The lancet oncology (01.05.2012)
Published in The lancet oncology (01.05.2012)
Get full text
Journal Article
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
Machiels, Jean-Pascal H, Prof, Haddad, Robert I, MD, Fayette, Jérôme, MD, Licitra, Lisa F, MD, Tahara, Makoto, MD, Vermorken, Jan B, Prof, Clement, Paul M, Prof, Gauler, Thomas, MD, Cupissol, Didier, MD, Grau, Juan José, MD, Guigay, Joël, Prof, Caponigro, Francesco, MD, de Castro, Gilberto, PhD, de Souza Viana, Luciano, MD, Keilholz, Ulrich, Prof, del Campo, Joseph M, MD, Cong, Xiuyu Julie, PhD, Ehrnrooth, Eva, MD, Cohen, Ezra E W, MD
Published in The lancet oncology (01.05.2015)
Published in The lancet oncology (01.05.2015)
Get full text
Journal Article
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
Yang, James Chih-Hsin, Prof, Shih, Jin-Yuan, MD, Su, Wu-Chou, Prof, Hsia, Te-Chun, MD, Tsai, Chun-Ming, Prof, Ou, Sai-Hong Ignatius, MD, Yu, Chung-Jen, Prof, Chang, Gee-Chen, MD, Ho, Ching-Liang, MD, Sequist, Lecia V, MD, Dudek, Arkadiusz Z, MD, Shahidi, Mehdi, MD, Cong, Xiuyu Julie, PhD, Lorence, Robert M, MD, Yang, Pan-Chyr, Prof, Miller, Vincent A, Dr
Published in The lancet oncology (01.05.2012)
Published in The lancet oncology (01.05.2012)
Get full text
Journal Article
A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments
Xu, Binghe, Ma, Fei, Wang, Tao, Wang, Shusen, Tong, Zhongsheng, Li, Wei, Wu, Xinhong, Wang, Xiaojia, Sun, Tao, Pan, Yueyin, Yao, Herui, Wang, Xian, Luo, Ting, Yang, Jin, Zeng, Xiaohua, Zhao, Weihong, Cong, Xiuyu Julie, Chen, Jiongjie
Published in International journal of cancer (15.05.2023)
Published in International journal of cancer (15.05.2023)
Get full text
Journal Article
Lack of a pharmacokinetic interaction between steady-state tipranavir/ritonavir and single-dose valacyclovir in healthy volunteers
Sabo, John P, Cong, Xiuyu (Julie), Kraft, Michael-Friedrich, Wallace, Lacey, Castles, Mark A, Mauss, Stefan, MacGregor, Thomas R
Published in European journal of clinical pharmacology (01.03.2011)
Published in European journal of clinical pharmacology (01.03.2011)
Get full text
Journal Article
Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)
Hirsh, Vera, Cadranel, Jacques, Cong, Xiuyu Julie, Fairclough, Diane, Finnern, Henrik W., Lorence, Robert M., Miller, Vince A., Palmer, Michael, Yang, James Chih-Hsin
Published in Journal of thoracic oncology (01.02.2013)
Published in Journal of thoracic oncology (01.02.2013)
Get full text
Journal Article
Abstract PO1-06-10: Overall survival results from EVER-132-001, a phase 2b single-arm study of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer
Ma, Fei, Wang, Shusen, Tong, Zhongsheng, Li, Wei, Wu, Xinhong, Wang, Xiaojia, Sun, Tao, Pan, Yueyin, Yao, Herui, Wang, Xian, Luo, Ting, Yang, Jin, Zeng, Xiaohua, Zhao, Weihong, Komatsubara, Kimberly, Nakamura, Rachel, Lai, Catherine, Zhang, Bo, Cong, Xiuyu, Xu, Binghe
Published in Cancer research (Chicago, Ill.) (02.05.2024)
Published in Cancer research (Chicago, Ill.) (02.05.2024)
Get full text
Journal Article
A randomized, open-label, phase II study of afatinib versus cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Analysis of stage 2 (S2) following crossover
Cupissol, Didier, Seiwert, Tanguy Y., Fayette, Jérôme, Ehrnrooth, Eva, Blackman, Alice Sarah, Cong, Xiuyu Julie, Cohen, Ezra E.W.
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
LUX-H&N 1: A phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy
Machiels, Jean-Pascal H., Licitra, Lisa F., Haddad, Robert I., Tahara, Makoto, Svensson, Liz, Cong, Xiuyu Julie, Ehrnrooth, Eva, Cohen, Ezra E. W.
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article